Clinical trials in Parkinson's disease dementia and dementia with Lewy bodies

Canadian Journal of Neurological Sciences

Volumn 34, Issue SUPPL. 1, 2007, Pages

  Camicioli, Richard ^a   Gauthier, Serge ^b  

^a GLENROSE REHABILITATION HOSPITAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE; ALPHA SYNUCLEIN; AMYLOID PROTEIN; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BIOLOGICAL MARKER; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; CLOZAPINE; CREATINE; DONEPEZIL; DOPAMINE RECEPTOR STIMULATING AGENT; GALANTAMINE; INOSITOL; LEVODOPA; MEMANTINE; N ACETYLASPARTIC ACID; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RASAGILINE; RIVASTIGMINE; TAU PROTEIN; ZIPRASIDONE;

ALZHEIMER DISEASE; BEHAVIOR DISORDER; BRAIN ATROPHY; BRAIN BLOOD FLOW; BRAIN DYSFUNCTION; CEREBROSPINAL FLUID; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; DAILY LIFE ACTIVITY; DEMENTIA; DIAGNOSTIC IMAGING; DISEASE COURSE; ECONOMIC ASPECT; FALLING; FUNCTIONAL STATUS; HUMAN; LEWY BODY; MINI MENTAL STATE EXAMINATION; MORTALITY; MOTOR DYSFUNCTION; NORADRENERGIC SYSTEM; NUCLEAR MAGNETIC RESONANCE IMAGING; NURSING HOME; OUTCOME ASSESSMENT; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SEROTONINERGIC SYSTEM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT FAILURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 34248598429     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/s0317167100005679     Document Type: Conference Paper

References (126)

1. Camicioli R, Fisher N. Progress in clinical neurosciences: Parkinson's disease with dementia and dementia with Lewy bodies. Can J Neurol Sci. 2004; 31 (1):7-21.
2. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996; 47 (5):1113-24.
3. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005; 65 (12):1863-72.
4. Tiraboschi P, Salmon DP, Hansen LA, Hofstetter RC, Thal LJ, Corey-Bloom J. What best differentiates Lewy body from Alzheimer's disease in early-stage dementia? Brain. 2006; 129 (Pt 3):729-35.
5. American Psychiatric Association; Diagnostic and statistical manual of mental disorders: DSM-IV. 4th ed. Washington, DC: American Psychiatric Association; 1994.
6. Burn DJ, Rowan EN, Minett T, Sanders J, Myint P, Richardson J, et al. Extrapyramidal features in Parkinson's disease with and without dementia and dementia with Lewy bodies: a cross-sectional comparative study. Mov Disord. 2003; 18 (8):884-9.
7. Boeve BF, Silber MH, Parisi JE, Dickson DW, Ferman TJ, Benarroch EE, et al. Synucleinopathy pathology and REM sleep behavior disorder plus dementia or parkinsonism. Neurology. 2003; 61 (1):40-5.
8. Miyasaki JM, Shannon K, Voon V, Ravina B, Kleiner-Fisman G, Anderson K, et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006; 66 (7):996-1002.
9. Stern Y, Tang MX, Jacobs DM, Sano M, Marder K, Bell K, et al. Prospective comparative study of the evolution of probable Alzheimer's disease and Parkinson's disease dementia. J Int Neuropsychol Soc. 1998; 4 (3):279-84.
10. Noe E, Marder K, Bell KL, Jacobs DM, Manly JJ, Stern Y. Comparison of dementia with Lewy bodies to Alzheimer's disease and Parkinson's disease with dementia. Mov Disord. 2004; 19 (1):60-7.
11. Hamilton JM, Salmon DP, Galasko D, Delis DC, Hansen LA, Masliah E, et al. A comparison of episodic memory deficits in neuropathologically-confirmed Dementia with Lewy bodies and Alzheimer's disease. J Int Neuropsychol Soc. 2004; 10 (5):689-97.
12. Simard M, van Reekum R, Myran D, Panisset M, Cohen T, Freedman M, et al. Differential memory impairment in dementia with Lewy bodies and Alzheimer's disease. Brain Cogn. 2002; 49 (2):244-9.
13. Collerton D, Burn D, McKeith I, O'Brien J. Systematic review and meta-analysis show that dementia with Lewy bodies is a visual-perceptual and attentional-executive dementia. Dement Geriatr Cogn Disord. 2003; 16 (4):229-37.
14. Lambon RMA, Powell J, Howard D, Whitworth AB, Garrard P, Hodges JR. Semantic memory is impaired in both dementia with Lewy bodies and dementia of Alzheimer's type: a comparative neuropsychological study and literature review. J Neurol Neurosurg Psychiatry. 2001; 70 (2)449-56.
15. Davis HS, Rockwood K. Conceptualization of mild cognitive impairment: a review. Int J Geriatr Psychiatry. 2004; 19 (4): 313-9.
16. Cormack F, Aarsland D, Ballard C, Tovee MJ. Pentagon drawing and neuropsychological performance in Dementia with Lewy bodies, Alzheimer's disease, Parkinson's disease and Parkinson's disease with dementia. Int J Geriatr Psychiatry. 2004; 19 (4): 371-7.
17. Ballard CG, Aarsland D, McKeith I, O'Brien J, Gray A, Cormack F, et al. Fluctuations in attention: PD dementia vs DLB with parkinsonism. Neurology. 2002; 59 (11):1714-20.
18. Downes JJ, Priestley NM, Doran M, Ferran J, Ghadiali E, Cooper P. Intellectual, mnemonic, and frontal functions in dementia with Lewy bodies: a comparison with early and advanced Parkinson's disease. Behav Neurol. 1998; 11 (3):173-83.
19. Boeve BF, Silber MH, Ferman TJ, Lucas JA, Parisi JE. Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Mov Disord. 2001; 16 (4):622-30.
20. Boeve BF, Silber MH, Ferman TJ. REM sleep behavior disorder in Parkinson's disease and dementia with Lewy bodies. J Geriatr Psychiatry Neurol. 2004; 17 (3):146-57.
21. Merdes AR, Hansen LA, Jeste DV, Galasko D, Hofstetter CR, Ho GJ, et al. Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology. 2003; 60 (10):1586-90.
22. Delis DC, Kramer JH, Kaplan E, Holdnack J. Reliability and validity of the Delis-Kaplan executive function system: an update. J Int Neuropsychol Soc. 2004; 10 (2):301-3.
23. Beatty WW, Ryder KA, Gontkovsky ST, Scott JG, McSwan KL, Bharucha KJ. Analyzing the subcortical dementia syndrome of Parkinson's disease using the RBANS. Arch Clin Neuropsychol. 2003; 18 (5):509-20.
24. Brown GG, Rahill AA, Gorell JM, McDonald C, Brown SJ, Sillanpaa M, et al. Validity of the Dementia rating scale in assessing cognitive function in Parkinson's disease. J Geriatr Psychiatry Neurol. 1999; 12 (4):180-8.
25. Peavy GM, Salmon D, Bear PI, Paulsen JS, Cahn DA, Hofstetter CR, et al. Detection of mild cognitive deficits in Parkinson's disease patients with the WAIS-R NI. J Int Neuropsychol Soc. 2001; 7 (5):535-43.
26. Marinus J, Visser M, Verwey NA, Verhey FR, Middelkoop HA, Stiggelbout AM, et al. Assessment of cognition in Parkinson's disease. Neurology. 2003; 61 (9):1222-8.
27. Royall DR, Lauterbach EC, Cummings JL, Reeve A, Rummans TA, Kaufer DI, et al. Executive control function: a review of its promise and challenges for clinical research. A report from the Committee on Research of the American Neuropsychiatric Association. J Neuropsychiatry Clin Neurosci. 2002; 14 (4): 377-405.
28. Wesnes KA, McKeith IG, Ferrara R, Emre M, Del Ser T, Spano PF, et al. Effects of rivastigmine on cognitive function in dementia with Lewy bodies: a randomized placebo-controlled international study using the cognitive drug research computerised assessment system. Dement Geriatr Cogn Disord. 2002; 13 (3):183-92.
29. Pate DS, Margolin DI. Cognitive slowing in Parkinson's and Alzheimer's patients: distinguishing bradyphrenia from dementia. Neurology. 1994; 44 (4):669-74.
30. Bradshaw J, Saling M, Hopwood M, Anderson V, Brodtmann A. Fluctuating cognition in dementia with Lewy bodies and Alzheimer's disease is qualitatively distinct. J Neurol Neurosurg Psychiatry. 2004; 75 (3):382-7.
31. Ferman TJ, Smith GE, Boeve BF, Ivnik RJ, Petersen RC, Knopman D, et al. DLB fluctuations: specific features that reliably differentiate DLB from AD and normal aging. Neurology. 2004; 62 (2):181-7.
32. Gelinas I, Gauthier L, McIntyre M, Gauthier S. Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia. Am J Occup Ther. 1999; 53 (5):471-81.
33. Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997; 11 Suppl 2:S33-9.
34. Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med. 2004; 351 (24):2509-18.
35. Aarsland D, Ballard C, Larsen JP, McKeith I. A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia. Int J Geriatr Psychiatry. 2001; 16 (5):528-36.
36. Weintraub D, Moberg PJ, Duda JE, Katz IR, Stern MB. Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease. J Am Geriatr Soc. 2004; 52 (5):784-8.
37. Norman S, Troster AI, Fields JA, Brooks R. Effects of depression and Parkinson's disease on cognitive functioning. J Neuropsychiatry Clin Neurosci. 2002; 14 (1):31-6.
38. Cubo E, Bernard B, Leurgans S, Raman R. Cognitive and motor function in patients with Parkinson's disease with and without depression. Clin Neuropharmacol. 2000; 23 (6):331-4.
39. Pluck GC, Brown RG. Apathy in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2002; 73 (6):636-42.
40. Isella V, Melzi P, Grimaldi M, Iurlaro S, Piolti R, Ferrarese C, et al. Clinical, neuropsychological, and morphometric correlates of apathy in Parkinson's disease. Mov Disord. 2002; 17 (2):366-71.
41. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994; 44 (12):2308-14.
42. Del Ser T, McKeith I, Anand R, Cicin-Sain A, Ferrara R, Spiegel R. Dementia with Lewy bodies: findings from an international multicentre study. Int J Geriatr Psychiatry. 2000; 15 (11): 1034-45.
43. McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomized, double-blind, placebo-controlled international study. Lancet. 2000; 356 (9247):2031-6.
44. Alexopoulos GS, Abrams RC, Young RC, Shamoian CA. Cornell scale for depression in Dementia. Biol Psychiatry. 1988; 23 (3):271-84.
45. Robert PH, Clairet S, Benoit M, Koutaich J, Bertogliati C, Tible O, et al. The apathy inventory: assessment of apathy and awareness in Alzheimer's disease, Parkinson's disease and mild cognitive impairment. Int J Geriatr Psychiatry. 2002; 17 (12):1099-105.
46. Lee VM, Giasson BI, Trojanowski JQ. More than just two peas in a pod: common amyloidogenic properties of tau and alpha-synuclein in neurodegenerative diseases. Trends Neurosci. 2004; 27 (3)429-34.
47. Perry EK, McKeith I, Thompson P, Marshall E, Kerwin J, Jabeen S, et al. Topography, extent, and clinical relevance of neurochemical deficits in dementia of Lewy body type, Parkinson's disease, and Alzheimer's disease. Ann N Y Acad Sci. 1991; 640:197-202.
48. Burton EJ, McKeith IG, Burn DJ, Williams ED, O'Brien JT. Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls. Brain. 2004; 127 (Pt 4):791-800.
49. Camicioli R, Moore MM, Kinney A, Corbridge E, Glassberg K, Kaye JA. Parkinson's disease is associated with hippocampal atrophy. Mov Disord. 2003; 18 (7):784-90.
50. Cousins DA, Burton EJ, Burn D, Gholkar A, McKeith IG, O'Brien JT. Atrophy of the putamen in dementia with Lewy bodies but not Alzheimer's disease: an MRI study. Neurology. 2003; 61 (9):1191-5.
51. Almeida OP, Burton EJ, McKeith I, Gholkar A, Burn D, O'Brien JT. MRI study of caudate nucleus volume in Parkinson's disease with and without dementia with Lewy bodies and Alzheimer's disease. Dement Geriatr Cogn Disord. 2003; 16 (2):57-63.
52. Middelkoop HA, van der Flier WM, Burton EJ, Lloyd AJ, Paling S, Barber R, et al. Dementia with Lewy bodies and AD are not associated with occipital lobe atrophy on MRI. Neurology. 2001; 57 (11):2117-20.
53. Barber R, McKeith I, Ballard C, O'Brien J. Volumetric MRI study of the caudate nucleus in patients with dementia with Lewy bodies, Alzheimer's disease, and vascular dementia. J Neurol Neurosurg Psychiatry. 2002; 72 (3):406-7.
54. O'Brien JT, Paling S, Barber R, Williams ED, Ballard C, McKeith IG, et al. Progressive brain atrophy on serial MRI in dementia with Lewy bodies, AD, and vascular dementia. Neurology. 2001; 56 (10):1386-8.
55. Molina JA, Garcia-Segura JM, Benito-Leon J, Gomez-Escalonilla C, del Ser T, Martinez V, et al. Proton magnetic resonance spectroscopy in dementia with Lewy bodies. Eur Neurol. 2002; 48 (3):158-63.
56. Summerfield C, Gomez-Anson B, Tolosa E, Mercader JM, Marti MJ, Pastor P, et al. Dementia in Parkinson disease: a proton magnetic resonance spectroscopy study. Arch Neurol. 2002; 59 (9):1415-20.
57. Camicioli RM, Korzan JR, Foster SL, Fisher NJ, Emery DJ, Bastos AC, et al. Posterior cingulate metabolic changes occur in Parkinson's disease patients without dementia. Neurosci Lett. 2004; 354 (3):477-80.
58. Firbank MJ, Colloby SJ, Burn DJ, McKeith IG, O'Brien JT. Regional cerebral blood flow in Parkinson's disease with and without dementia. Neuroimage. 2003; 20 (2):1309-19.
59. Colloby S, O'Brien J. Functional imaging in Parkinson's disease and dementia with Lewy bodies. J Geriatr Psychiatry Neurol. 2004; 17 (3):158-63.
60. Gilman S, Koeppe RA, Little R, An H, Junck L, Giordani B, et al. Striatal monoamine terminals in Lewy body dementia and Alzheimer's disease. Ann Neurol. 2004; 55 (6):774-80.
61. Plotkin M, Amthauer H, Klaffke S, Kuhn A, Ludemann L, Arnold G, et al. Combined (123)I-FP-CIT and (123)I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients. J Neural Transm. 2005;112(5):677-92.
62. O'Brien JT, Colloby S, Fenwick J, Williams ED, Firbank M, Burn D, et al. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol. 2004; 61 (6):919-25.
63. Walker Z, Costa DC, Walker RW, Lee L, Livingston G, Jaros E, et al. Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease: a comparison. Neurology. 2004; 62 (9):1568-72.
64. Bohnen NI, Kaufer DI, Ivanco LS, Lopresti B, Koeppe RA, Davis JG, et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol. 2003; 60 (12):1745-8.
65. Gomez-Tortosa E, Gonzalo I, Fanjul S, Sainz MJ, Cantarero S, Cemillan C, et al. Cerebrospinal fluid markers in dementia with Lewy bodies compared with Alzheimer disease. Arch Neurol. 2003; 60(9):1218-22.
66. Hanyu H, Shimizu S, Hirao K, Kanetaka H, Iwamoto T, Chikamori T, et al. Comparative value of brain perfusion SPECT and [(123)I]MIBG myocardial scintigraphy in distinguishing between dementia with Lewy bodies and Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2006; 33 (3):248-53.
67. Kaufer DI, Catt KE, Lopez OL, DeKosky ST. Dementia with Lewy bodies: response of delirium-like features to donepezil. Neurology. 1998; 51 (5):1512.
68. Shea C, MacKnight C, Rockwood K. Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients. Int Psychogeriatr. 1998; 10 (3):229-38.
69. Aarsland D, Bronnick K, Karlsen K. Donepezil for dementia with Lewy bodies: a case study. Int J Geriatr Psychiatry. 1999; 14 (1):69-72.
70. Samuel W, Caligiuri M, Galasko D, Lacro J, Marini M, McClure FS, et al. Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study. Int J Geriatr Psychiatry. 2000; 15 (9):794-802.
71. Querfurth HW, Allam GJ, Geffroy MA, Schiff HB, Kaplan RF. Acetylcholinesterase inhibition in dementia with Lewy bodies: results of a prospective pilot trial. Dement Geriatr Cogn Disord. 2000; 11 (6):314-21.
72. McKeith IG, Grace JB, Walker Z, Byrne EJ, Wilkinson D, Stevens T, et al. Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial. Int J Geriatr Psychiatry. 2000; 15 (5):387-92.
73. Grace J, Daniel S, Stevens T, Shankar KK, Walker Z, Byrne EJ, et al. Long-term use of rivastigmine in patients with dementia with Lewy bodies: an open-label trial. Int Psychogeriatr. 2001; 13 (2):199-205.
74. Maclean LE, Collins CC, Byrne EJ. Dementia with Lewy bodies treated with rivastigmine: effects on cognition, neuropsychiatric symptoms, and sleep. Int Psychogeriatr. 2001; 13 (3):277-88.
75. Edwards KR, Hershey L, Wray L, Bednarczyk EM, Lichter D, Farlow M, et al. Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 12-week interim analysis. Dement Geriatr Cogn Disord. 2004; 17 Suppl 1:S40-8.
76. Holm AC. Alleviation of multiple abnormalities by galantamine treatment in two patients with dementia with Lewy bodies. Am J Alzheimers Dis Other Demen. 2004; 19 (4):215-8.
77. Wild R, Pettit T, Burns A. Cholinesterase inhibitors for dementia with Lewy bodies. Cochrane Database Syst Rev 2003; (3):CD003672.
78. McKeith IG, Wesnes KA, Perry E, Ferrara R. Hallucinations predict attentional improvements with rivastigmine in dementia with Lewy bodies. Dement Geriatr Cogn Disord. 2004; 18 (1):94-100.
79. Pakrasi S, Mukaetova-Ladinska EB, McKeith IG, O'Brien JT. Clinical predictors of response to Acetyl Cholinesterase Inhibitors: experience from routine clinical use in Newcastle. Int J Geriatr Psychiatry. 2003; 18 (10):879-86.
80. Werber EA, Rabey JM. The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson's disease and dementia. J Neural Transm. 2001; 108 (11):1319-25.
81. Hutchinson M, Fazzini E. Cholinesterase inhibition in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1996; 61 (3):324-5.
82. Aarsland D, Litvan I, Salmon D, Galasko D, Wentzel-Larsen T, Larsen JP. Performance on the dementia rating scale in Parkinson's disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy and Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2003; 74 (9):1215-20.
83. Leroi I, Brandt J, Reich SG, Lyketsos CG, Grill S, Thompson R, et al. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. Int J Geriatr Psychiatry. 2004; 19 (1):1-8.
84. Ravina B, Putt M, Siderowf A, Farrar JT, Gillespie M, Crawley A, et al. Donepezil for dementia in Parkinson's disease: a randomized, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry. 2005; 76 (7):934-9.
85. Minett TS, Thomas A, Wilkinson LM, Daniel SL, Sanders J, Richardson J, et al. What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson's disease with dementia. Int J Geriatr Psychiatry. 2003; 18 (11):988-93.
86. Thomas AJ, Burn DJ, Rowan EN, Littlewood E, Newby J, Cousins D, et al. A comparison of the efficacy of donepezil in Parkinson's disease with dementia and dementia with Lewy bodies. Int J Geriatr Psychiatry. 2005; 20 (10):938-44.
87. Richard IH, Justus AW, Greig NH, Marshall F, Kurlan R. Worsening of motor function and mood in a patient with Parkinson's disease after pharmacologic challenge with oral rivastigmine. Clin Neuropharmacol. 2002; 25 (6):296-9.
88. Onofrj M, Thomas A. Severe worsening of parkinsonism in Lewy body dementia due to donepezil. Neurology 2003; 61 (10):1452.
89. Giladi N, Shabtai H, Gurevich T, Benbunan B, Anca M, Korczyn AD. Rivastigmine (Exelon) for dementia in patients with Parkinson's disease. Acta Neurol Scand. 2003; 108 (5):368-73.
90. Fogelson N, Kogan E, Korczyn AD, Giladi N, Shabtai H, Neufeld MY. Effects of rivastigmine on the quantitative EEG in demented Parkinsonian patients. Acta Neurol Scand. 2003; 107 (4):252-5.
91. Bullock R, Cameron A. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series. Curr Med Res Opin. 2002; 18 (5):258-64.
92. Bergman J, Lerner V. Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease. Clin Neuropharmacol. 2002; 25 (2):107-10.
93. Wesnes KA, McKeith I, Edgar C, Emre M, Lane R. Benefits of rivastigmine on attention in dementia associated with Parkinson disease. Neurology. 2005; 65 (10):1654-6.
94. Poewe W, Wolters E, Emre M, Onofrj M, Hsu C, Tekin S, et al. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study. Mov Disord. 2006; 21 (4):456-61.
95. Aarsland D, Hutchinson M, Larsen JP. Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia. Int J Geriatr Psychiatry. 2003; 18 (10):937-41.
96. Maidment I, Fox C, Boustani M. Cholinesterase inhibitors for Parkinson's disease dementia. Cochrane Database Syst Rev. 2006; (1):CD004747.
97. Ballard C, Grace J, McKeith I, Holmes C. Neuroleptic sensitivity in dementia with Lewy bodies and Alzheimer's disease. Lancet. 1998; 351 (9108):1032-3.
98. The French Clozapine Parkinson Study Group. Clozapine in drug-induced psychosis in Parkinson's disease. Lancet. 1999; 353 (9169):2041-2.
99. Pollak P, Tison F, Rascol O, Destee A, Pere JJ, Senard JM, et al. Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry. 2004; 75 (5):689-95.
100. The Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med. 1999; 340 (10):757-63.
101. Factor SA, Friedman JH, Lannon MC, Oakes D, Bourgeois K. Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: results of the 12 week open label extension in the PSYCLOPS trial. Mov Disord. 2001; 16 (1):135-9.
102. Ondo WG, Levy JK, Vuong KD, Hunter C, Jankovic J. Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord. 2002; 17 (5):1031-5.
103. Breier A, Sutton VK, Feldman PD, Kadam DL, Ferchland I, Wright P, et al. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease. Biol Psychiatry. 2002; 52 (5):438-45.
104. Goetz CG, Blasucci LM, Leurgans S, Pappert EJ. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology. 2000; 55 (6):789-94.
105. Morgante L, Epifanio A, Spina E, Zappia M, Di Rosa AE, Marconi R, et al. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol. 2004; 27 (4):153-6.
106. Carson S, McDonagh MS, Peterson K. A systematic review of the efficacy and safety of atypical antipsychotics in patients with psychological and behavioral symptoms of dementia. J Am Geriatr Soc. 2006; 54 (2):354-61.
107. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005; 294 (15):1934-43.
108. Juncos JL, Roberts VJ, Evatt ML, Jewart RD, Wood CD, Potter LS, et al. Quetiapine improves psychotic symptoms and cognition in Parkinson's disease. Mov Disord. 2004; 19 (1):29-35.
109. Targum SD, Abbott JL. Efficacy of quetiapine in Parkinson's patients with psychosis. J Clin Psychopharmacol. 2000; 20 (1):54-60.
110. Fernandez HH, Trieschmann ME, Burke MA, Jacques C, Friedman JH. Long-term outcome of quetiapine use for psychosis among Parkinsonian patients. Mov Disord. 2003; 18 (5):510-4.
111. Fernandez HH, Trieschmann ME, Friedman JH. Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience. Clin Neuropharmacol. 2004; 27 (1):4-5.
112. Ondo WG, Tintner R, Dat Voung K, Lai D, Ringholz G. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov Disord. 2005; 20(8):958-63.
113. Fernandez HH, Trieschmann ME, Burke MA, Friedman JH. Quetiapine for psychosis in Parkinson's disease versus dementia with Lewy bodies. J Clin Psychiatry. 2002; 63 (6):513-5.
114. Bonelli SB, Ransmayr G, Steffelbauer M, Lukas T, Lampl C, Deibl M. L-dopa responsiveness in dementia with Lewy bodies, Parkinson disease with and without dementia. Neurology. 2004; 63 (2):376-8.
115. Molloy S, McKeith IG, O'Brien JT, Burn DJ. The role of levodopa in the management of dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2005; 76 (9):1200-3.
116. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003; 348 (14):1333-41.
117. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004; 291 (3):317-24.
118. Ridha BH, Josephs KA, Rossor MN. Delusions and hallucinations in dementia with Lewy bodies: worsening with memantine. Neurology. 2005; 65 (3):481-2.
119. Sabbagh MN, Hake AM, Ahmed S, Farlow MR. The use of memantine in dementia with Lewy bodies. J Alzheimers Dis. 2005; 7 (4):285-9.
120. Schapira AH. Disease modification in Parkinson's disease. Lancet. Neurol 2004; 3 (6):362-8.
121. Citron M. Strategies for disease modification in Alzheimer's disease. Nat Rev Neurosci. 2004; 5 (9):677-85.
122. Mani RB. The evaluation of disease modifying therapies in Alzheimer's disease: a regulatory viewpoint. Stat Med. 2004; 23 (2):305-14.
123. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol. 2004; 61 (4):561-6.
124. Schneider LS, Olin JT, Lyness SA, Chui HC. Eligibility of Alzheimer's disease clinic patients for clinical trials. J Am Geriatr Soc. 1997; 45 (8):923-8.
125. Mitchell SL, Sullivan EA, Lipsitz LA. Exclusion of elderly subjects from clinical trials for Parkinson disease. Arch Neurol. 1997; 54 (11):1393-8.
126. Dymek MP, Atchison P, Harrell L, Marson DC. Competency to consent to medical treatment in cognitively impaired patients with Parkinson's disease. Neurology. 2001; 56 (1):17-24.